Paper Details

  1. Home
  2. Paper Details

[Autologous transplantation of peripheral hematopoietic cells and subsequent maintenance therapy with interferon alpha or interferon alpha and dexamethasone in patients with multiple myeloma--results from the 4W randomized clinical trial of the Czech Myeloma Group].

Author: AdamZ, BacovskýJ, CahováS, DusekL, FaberE, FrankováH, GumulecJ, HausdorfP, HájekR, IndrákK, JanuskaJ, KesslerP, KozaV, KrejcíM, KrálováE, KucaB, LehankaF, LeníckováS, MayerJ, MeluzínováI, NovosadováL, PozdĕnováV, PraskacP, RezekZ, SchützováM, ScudlaV, StavarováY, StefánekI, SumnáE, SyobodníkA, VeprekK, VorlícekJ, VránováM, WalterováL

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This clinical study (4W) involved 167 patients with newly diagnosed multiple myeloma. Treatment involved induction chemotherapy, stem cell mobilization, and autologous transplantation. Patients were then randomized into two groups for maintenance treatment: one received interferon alpha and the other received alternating cycles of interferon alpha and dexamethasone. Of the 113 patients evaluated after transplantation, 12% achieved complete remission, 56% achieved remission, and 21% achieved partial remission. The mortality rate during transplantation was 2.67%. There was no significant difference between the two maintenance treatment groups in terms of the time before disease relapse. The median survival has not yet been reached.
Paper Details　
Original Abstract of the Article :
In the clinical 4W study patients with newly diagnosed multiple myeloma are included where the state of the disease calls for treatment, while high dose chemotherapy is not contraindicated. Treatment according to protocol 4W comprises induction chemotherapy VAD, mobilization of haematopoietic cells ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/11693062

データ提供：米国国立医学図書館（NLM）

Autologous Transplantation: A New Approach to Fighting Multiple Myeloma

Multiple myeloma, a cancer that affects the bone marrow, is a formidable desert beast. This study explores the effectiveness of [autologous transplantation], a treatment that involves harvesting and re-infusing a patient's own stem cells, for patients with multiple myeloma. The researchers conducted a [clinical trial] to compare the outcomes of two maintenance therapies following autologous transplantation: [interferon alpha] and a combination of [interferon alpha and dexamethasone].

A Promising Path in the Fight Against Multiple Myeloma

The study found that autologous transplantation followed by either interferon alpha or a combination of interferon alpha and dexamethasone resulted in significant remission rates, including complete remission in 12% of patients. These results highlight the potential of autologous transplantation as a valuable tool in the fight against multiple myeloma.

Navigating the Challenges of Cancer Treatment

This study underscores the importance of ongoing research and development in cancer treatment. It offers a glimmer of hope for individuals battling multiple myeloma, providing a path towards a more hopeful future. It is a reminder that even in the harshest deserts, there can be oases of innovation and progress.

Dr. Camel's Conclusion

This study provides valuable insights into the potential of autologous transplantation as a treatment for multiple myeloma. It demonstrates that this approach can lead to significant remission rates and offers hope for a brighter future for individuals battling this challenging disease. It is a testament to the enduring spirit of medical researchers who continue to seek new solutions to overcome the challenges of cancer.

Date :
  1. Date Completed 2001-12-07
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

11693062

DOI: Digital Object Identifier

11693062

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

Czech

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.